Unknown PHASE1 INTERVENTIONAL 1-arm NCT05420493

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

This is a Phase I Clinical Study to Evaluate the Safety and Efficacy of CAR-T Infusion Preparation in the Treatment of CD19-positive Relapsed/Refractory Non-Hodgkin Lymphoma.

Sponsor: Chongqing Precision Biotech Co., Ltd

Conditions Non Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma

Interventions CAR-T cells

Updated 6 times since 2022 Last updated: Jan 2, 2024 Started: Sep 6, 2021 Primary completion: Sep 30, 2024 Completion: Sep 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Non Hodgkin Lymphoma and Refractory Non-Hodgkin Lymphoma and is currently ongoing. Chongqing Precision Biotech Co., Ltd leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jul 2022 — Dec 2023 [monthly]

Recruiting PHASE1

First recorded

Sep 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chongqing Precision Biotech Co., Ltd

Data source: Chongqing Precision Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China